Clinical Trials Logo

Clinical Trial Summary

This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in combination with pemetrexed+cisplatin/carboplatin in subjects with previously untreated metastatic non-squamous NSCLC. The main hypothesis of the study is that BCD-100 in combination with chemotherapy prolongs OS compared to placebo with chemotherapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03912389
Study type Interventional
Source Biocad
Contact Fedor B Krykov, MD, PhD
Phone +7-(812)-380-49-33
Email biocad@biocad.ru
Status Recruiting
Phase Phase 3
Start date June 1, 2019
Completion date December 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Recruiting NCT05853887 - Liquid Biopsy Based NGS in Newly Diagnosed NSCLC N/A
Terminated NCT04265534 - KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC Phase 2
Terminated NCT04698681 - NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
Completed NCT03779191 - Alectinib in Combination With Bevacizumab in ALK Positive NSCLC Phase 2